Dr. Brian Olshansky, MD, practicing cardiac electrophysiologist and professor emeritus at University of Iowa, discusses the importance of treating symptomatic nOH. Dr. Olshansky is a paid consultant and has received grants from Lundbeck. The information provided herein is intended only for U.S. healthcare professionals.
Brian Olshansky, MD
University of Iowa
Mason City and Waterloo, Iowa
Learn more about NORTHERA® (droxidopa)
View efficacy and safety data
Full Prescribing Information
INDICATIONS AND IMPORTANT SAFETY INFORMATION
NORTHERA (droxidopa) is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson’s disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically.
WARNING: SUPINE HYPERTENSION
Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA.
For more information, please see the full Prescribing Information, including Boxed Warning for supine hypertension.
©2019 Lundbeck. All rights reserved. NORTHERA is a registered trademark of Lundbeck NA Ltd. DRX-B-100194
Please click on Next tab to advance through activity.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.